Clinical trialNCT05521698RecruitingPhase 1Interventional

A Randomized Trial of Bicalutamide in Non-Muscle Invasive Bladder Cancer

SponsorUniversity of Wisconsin, MadisonEnrollment80Non-Muscle Invasive Bladder Urothelial CarcinomaRecurrent Non-Muscle Invasive Bladder Urothelial Carcinoma

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This phase I trial evaluates the effects of bicalutamide, compared to no study drug (NSD), on epidermal growth factor receptor (EGFR) protein expression in patients with non-muscle invasive bladder cancer. Bicalutamide is in a class of medications called androgen receptor inhibitors. It works by blocking the effects of androgen (a male reproductive hormone) to stop the growth and spread of tumor cells. Previous studies have suggested that expression of a protein called EGFR on tumor cells is related to bladder cancer disease progression. This trial may help doctors evaluate if bicalutamide has any effect on EGFR expression in patients with non-muscle invasive bladder cancer.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Edward M Messing
University of Wisconsin, Madison
Principal Investigator
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

6 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

University of Arizona Cancer Center - Prevention Research Clinic
Tucson, Arizona, United States
Juan Chipollini
Recruiting
Cedars Sinai Medical Center
Los Angeles, California, United States
Michael A. Ahdoot
Not, yet, recruiting
National Cancer Institute Urologic Oncology Branch
Bethesda, Maryland, United States
Sandeep Gurram
Not, yet, recruiting
University of Rochester
Rochester, New York, United States
Edward M. Messing
Not, yet, recruiting
Ohio State University Comprehensive Cancer Center
Columbus, Ohio, United States
Debasish Sundi
Not, yet, recruiting
University of Wisconsin Carbone Cancer Center - University Hospital
Madison, Wisconsin, United States
Kyle A. Richards
Recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Bicalutamide →

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 25 Jun 2026
Primary completion: 1 Jun 2028
Completion: 1 Dec 2028
Last update posted: 7 Jul 2026
Registered enrollment: 80
Registry id: NCT05521698

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.